Ask VialBase
Research

Semaglutide Effects on Heart Disease and Stroke in Patients Who Are Overweight or Obese (SELECT) — VialBase Research

Trial Summary

SELECT was a landmark cardiovascular outcomes trial (CVOT) evaluating semaglutide 2.4 mg in overweight/obese adults with established atherosclerotic cardiovascular disease but without diabetes. This was the first trial to demonstrate that a GLP-1 RA reduces MACE in a non-diabetic population purely on the basis of weight management.

Design

  • Type: Randomized, double-blind, placebo-controlled, event-driven
  • Population: 17,604 adults aged 45+ with BMI 27+ and established CVD, without diabetes
  • Arms: Semaglutide 2.4 mg SC weekly vs. placebo
  • Duration: Median follow-up ~40 months
  • Primary endpoint: 3-point MACE (CV death, non-fatal MI, non-fatal stroke)

Key Outcomes

  • Primary endpoint met: 20% reduction in MACE (HR 0.80, 95% CI 0.72-0.90, p<0.001)
  • CV death reduced by 15%, non-fatal MI by 28%, non-fatal stroke by 7%
  • Mean weight loss: ~9.4% with semaglutide vs. ~0.9% placebo
  • Benefits emerged early and were consistent across subgroups
  • Led to expanded FDA labeling for cardiovascular risk reduction
  • Results published in NEJM (2023)

Significance for Peptide Research

SELECT fundamentally changed the clinical positioning of GLP-1 RAs from “diabetes/obesity drugs” to “cardiometabolic medicines.” The 20% MACE reduction in non-diabetic patients established that the cardiovascular benefits of semaglutide are independent of glucose control and likely driven by anti-inflammatory, anti-atherosclerotic, and weight-mediated mechanisms. This trial is a cornerstone reference for the GLP-1 RA cardiovascular benefit evidence base.

See Also